Business Wire

CA-TULA-TECHNOLOGY

Share
Liebherr and Tula Join Research Activities

At the International Engine Congress in Baden-Baden (Germany), Liebherr-Components AG and U.S.-based Tula Technology presented the results of their joint study on heavy machinery. Together, the companies carried out research on reducing greenhouse gases (GHG) and nitrogen oxides (NOX ) produced by heavy-duty equipment. Based on simulations, Tula’s diesel Dynamic Skip Fire (dDSF™) software allows the reduction of NOX tailpipe emissions by 41% and carbon dioxide (CO2 ) by 9.5%. For this study, Liebherr Machines Bulle SA provided its D966 engine that operates in a variety of applications, like mobile or maritime cranes and wheel loaders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005030/en/

Integration of software into other Liebherr engines possible

The results of the research could influence the development or manufacturing of off-road equipment worldwide in a positive way. Therefore, Liebherr-Components will continue its activities in designing a “proof of concept” hardware for the integration of Tula’s dDSF software into their engine system. The D966, a very compact 13.5L 6-cylinder diesel engine, will also be used in further tests. In the next step, Liebherr will consider the integration of the dDSF software into other engines in its portfolio.

"Liebherr is a forward-thinking company focusing already today on the challenges that customers around the world will face tomorrow,” says Ulrich Weiss, Managing Director for Research and Development of Combustion Engines at Liebherr Machines Bulle SA. “The reduction of greenhouse gases and nitrogen oxide emissions is the goal that we strive to achieve, while continuously improving our engine’s performance.” The results of the joint study indicate that dDSF plays an important role in addressing these challenges, being part of future solutions, which will help in reaching zero emissions.

Efficient engine operation and low level of tailpipe emissions

R. Scott Bailey, the President and Chief Executive Officer of Tula Technology, explains: “At Tula, we are driven by a passion to increase efficiency in engines and motors of all types and also improve the environment. While there are existing regulations to reduce emissions in off-road machinery and vehicles, more stringent standards are expected within the decade. To comply, equipment manufacturers need solutions like our patented dDSF software to operate engines more efficiently and produce dramatically lower levels of tailpipe emissions.”

Tula’s technologies provide cost-effective solutions that are proven to increase engine efficiency. In series production since 2018, Dynamic Skip Fire (DSF®) uses patented algorithms that choose to skip or fire individual cylinders dynamically to meet an engine’s torque demands. This enables near-peak engine efficiency for cleaner burning, as well as more fuel-efficient vehicles. Noise and vibration are proactively mitigated by manipulating the firing pattern and cylinder loading. As a result, DSF has been deployed in more than 1.5 million passenger vehicles to date. The released study adds to the growing list of successful applications of Tula’s technology for diesel dDSF, including passenger cars, commercial vehicles and heavy machinery – with its main goal to reduce GHG and NOX as major contributors to global warming.

About Tula Technology, Inc.

Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technologies and a robust global patent portfolio of more than 380 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .

About Liebherr-Components AG

In this segment, the Liebherr Group specialises in the development, design, and manufacturing of high-performance components in the field of mechanical, hydraulic and electric drive and control technology. Liebherr-Component Technologies AG, based in Bulle (Switzerland), coordinates all activities in the Components product segment. The extensive product range includes combustion engines, injection systems, engine control units, axial piston pumps and motors, hydraulic cylinders, slewing bearings, gearboxes and winches, switchgear, electronic and power electronics components, and software. The high-quality components are used in cranes and earthmoving machinery, in the mining industry, maritime applications, wind turbines, automotive engineering or in aviation and transport technology. Synergy effects in other product segments of the Liebherr Group are used to drive continuous technological development.

About the Liebherr Group

The Liebherr Group is a family-run technology company with a highly diversified product portfolio. The company is one of the largest construction equipment manufacturers in the world. It also provides high-quality and user-oriented products and services in a wide range of other areas. The Liebherr Group includes over 140 companies across all continents. In 2020, it employed around 48,000 staff and achieved combined revenues of over 10.3 billion euros. Liebherr was founded in Kirchdorf an der Iller in Southern Germany in 1949. Since then, the employees have been pursuing the goal of achieving continuous technological innovation, and bringing industry-leading solutions to its customers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye